Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron Drug-Drug Interaction Study in Healthy Overweight and Obese Participants
NCT06186622Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of orforglipron in obesity (2 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration-Time Curve at 120 hours and Maximum Observed Concentration at 120 hours. Started Jan 2024; status: completed.
02
Drugs
orforglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06186622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06186622.